Description

Product Description

Introduction

Dirucotide, also known as MBP8298, is a synthetic 17-amino acid peptide designed to replicate a specific segment of human myelin basic protein (MBP). MBP is an essential component of the myelin sheath that insulates nerve fibers within the central nervous system (CNS). Because autoimmune attacks against MBP are implicated in diseases such as multiple sclerosis (MS), Dirucotide has emerged as a valuable research compound for exploring immune tolerance, T-cell recognition, and peptide-based immunotherapy.

Structural & Biochemical Features

• Peptide Class: Synthetic immunological peptide

• Amino Acid Length: 17 residues

• Sequence Identity: Identical to a portion of human MBP

• Molecular Properties: Mimics natural myelin epitopes, enabling interaction with immune receptors

• Biological Role: Experimental induction of immune tolerance

The structural fidelity of Dirucotide allows researchers to study autoimmune targeting mechanisms and explore potential therapeutic immunomodulation strategies.

Relevance in Autoimmune Research

Autoimmune diseases of the CNS, particularly multiple sclerosis, are characterized by autoreactive T-cells that recognize MBP and attack the myelin sheath. By mimicking MBP epitopes, Dirucotide can modulate T-cell activity, making it an essential tool for:

• Investigating immune tolerance induction

• Studying antigen-specific T-cell responses

• Exploring peptide immunotherapy strategies for MS

• Developing preclinical autoimmune models

Production & Purity

Dirucotide is manufactured under GMP-compliant peptide synthesis protocols and is available at ?98% purity (HPLC verified). It is supplied in a lyophilized, stable form suitable for long-term storage and reproducible laboratory studies.

Product Specifications

The high purity, sequence fidelity, and GMP manufacturing of Dirucotide provide reproducibility in sensitive immunological experiments.

Mechanism of Action & Research Applications

Mechanism of Action

Dirucotide acts by mimicking a natural MBP epitope, presenting immune cells with a synthetic yet biologically recognizable sequence. This has two primary effects in research contexts:

1. Immune Recognition Studies

   • Helps characterize how autoreactive T-cells bind and respond to MBP peptides.

2. Immune Tolerance Research

   • May induce an immune-tolerant state by repeatedly exposing the immune system to the MBP epitope without triggering destructive autoimmunity.

This dual role makes Dirucotide a powerful model compound in autoimmune research.

Research Applications

• Multiple Sclerosis (MS) Models
  Used to study autoreactive T-cell responses and test experimental immunotherapies.

• Peptide Immunotherapy Development
  Provides a basis for antigen-specific treatments targeting autoimmunity.

• Mechanistic Immunology Studies
  Explores the relationship between peptide antigens, MHC presentation, and T-cell activity.

• Tolerance Induction Models
  Evaluates whether repeated peptide exposure can downregulate autoimmune responses.

• Biomarker Discovery
  Identifies immunological signatures associated with peptide-induced tolerance.

  

Side Effects (For Reference in Research Models)

While Dirucotide is not a therapeutic agent, experimental studies in laboratory models have documented the following considerations:

• Immune Response Variability: Depending on genotype, immune response to Dirucotide may vary significantly.

• Autoimmune Activation: In some models, exposure may exacerbate immune reactivity instead of tolerance.

• Solvent Sensitivity: Peptide solubility depends on proper dissolution (e.g., PBS or DMSO).

• Dosage-Dependent Effects: Both tolerance induction and activation may occur depending on dosing.

• Experimental Limitations: Observations in animal models may not fully extrapolate to human systems.

Researchers must carefully control dose, solvent, and experimental design to ensure reproducibility and minimize unwanted immunological variability.

Disclaimer

For research use only. Not intended for human or veterinary administration.

Keywords

• Dirucotide CAS 152074-97-0

• MBP8298 synthetic peptide

• Dirucotide autoimmune research

• Dirucotide multiple sclerosis studies

• Myelin basic protein peptide research

• Synthetic peptide for CNS immunology

• GMP peptide autoimmune tolerance

• Dirucotide preclinical immunotherapy

• Dirucotide peptide immunology

• Autoimmune CNS research peptide